Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| IL17A mAb | Monospecific antibody | Immunological disease | Psoriasis,Axial spondyloarthritis SpA | Phase III | Global (except China) |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ILA-H5243 | Human | Human IL-17A / CTLA-8 Protein, His Tag (HPLC verified) |  |
|
|
| CEA-C092 | Human | ClinMax™ Human IL-17A / CTLA8 ELISA Kit | |||
| EP-140 | Human | IL-17A : IL-17RA [Biotinylated] Inhibitor Screening ELISA Kit | |||
| EP-139 | Human | IL-17A [Biotinylated] : IL-17RA Inhibitor Screening ELISA Kit | |||
| ILA-H5219 | Human | Human IL-17A / CTLA-8 Protein, premium grade |  |
|
|
| ILA-C52H7 | Canine | Canine IL-17A / CTLA-8 Protein, His Tag |  |
|
|
| ILA-C5249 | Cynomolgus | Cynomolgus IL-17A / CTLA-8 Protein, His Tag (MALS verified) |  |
|
|
| ILA-H82Q1 | Human | Biotinylated Human IL-17A / CTLA-8 Protein, His,Avitag™ |  |
|
|
| CT8-M5240 | Mouse | Mouse IL-17A / CTLA-8 Protein, His Tag (MALS verified) |  |
|
|
Human IL-17A, premium grade (Cat. No. ILA-H5219) stimulates proliferation of 293F-NFKB/luc-IL17-30 cell line. The specific activity of Human IL-17A, premium grade is > 1.00ⅹ10^7 IU/mg, which is calibrated against human IL-17 WHO International Standard (NIBSC code: 01/420) (QC tested).
Human IL-17 RA Protein, Fc Tag (Cat. No. ILA-H525f) captured on Protein A Chip can bind Human IL-17A Protein, His Tag (Cat. No. ILA-H5243) with an affinity constant of 0.360 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ixekizumab | LY-2439821 | Approved | Eli Lilly And Company | 拓咨, Taltz | United States | Psoriasis | Eli Lilly And Company | 2016-03-22 | Diabetes Mellitus, Type 1; Non-radiographic axial spondyloarthritis; Depressive Disorder, Major; Pyoderma Gangrenosum; Spondylarthritis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Lichen Planus; Pemphigoid, Bullous; Pityriasis Rubra Pilaris; Plaque psoriasis | Details |
| Virulizin | Approved | Aptose | Virulizin, Virulizin-2 gamma | Mexico | Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | null | 1997-01-01 | Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Sarcoma, Kaposi; Melanoma; Uterine Cervical Neoplasms | Details | |
| Secukinumab | NVP-AIN-457; AIN-457; KB-03303A | Approved | Novartis Pharma Ag | 可善挺, Scapho, Cosentyx | Japan | Arthritis, Psoriatic; Psoriasis | Novartis Pharma Ag | 2014-12-26 | Hidradenitis Suppurativa; Polymyalgia Rheumatica; Ichthyosis, Lamellar; Psoriasis; Tendinopathy; Hyperkeratosis, Epidermolytic; Arthritis, Psoriatic; Tendon Injuries; Asthma; Lichen Planus; Arthritis, Juvenile; Uveitis; Arthritis; Inflammation; Plaque psoriasis; Behcet Syndrome; Crohn Disease; Gastroenteritis; Dermatitis, Atopic; Ichthyosiform Erythroderma, Congenital; Spondylitis, Ankylosing; Non-radiographic axial spondyloarthritis; Necrobiosis Lipoidica; Diabetes Mellitus, Type 1; Giant Cell Arteritis; Alopecia Areata; Pyoderma Gangrenosum; Lupus Erythematosus, Discoid; Metabolic Dysfunction-Associated Steatotic Liver Disease; Inflammatory Bowel Diseases; Multiple Sclerosis, Relapsing-Remitting; Rotator Cuff Injuries; Spondylarthritis; Arthritis, Rheumatoid; Spondylarthropathies; Netherton Syndrome; Ichthyosis; Lupus Nephritis; Graves Ophthalmopathy; Multiple Sclerosis | Details |
| Ixekizumab | LY-2439821 | Approved | Eli Lilly And Company | 拓咨, Taltz | United States | Psoriasis | Eli Lilly And Company | 2016-03-22 | Diabetes Mellitus, Type 1; Non-radiographic axial spondyloarthritis; Depressive Disorder, Major; Pyoderma Gangrenosum; Spondylarthritis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Lichen Planus; Pemphigoid, Bullous; Pityriasis Rubra Pilaris; Plaque psoriasis | Details |
| Virulizin | Approved | Aptose | Virulizin, Virulizin-2 gamma | Mexico | Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | null | 1997-01-01 | Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Sarcoma, Kaposi; Melanoma; Uterine Cervical Neoplasms | Details | |
| Secukinumab | NVP-AIN-457; AIN-457; KB-03303A | Approved | Novartis Pharma Ag | 可善挺, Scapho, Cosentyx | Japan | Arthritis, Psoriatic; Psoriasis | Novartis Pharma Ag | 2014-12-26 | Hidradenitis Suppurativa; Polymyalgia Rheumatica; Ichthyosis, Lamellar; Psoriasis; Tendinopathy; Hyperkeratosis, Epidermolytic; Arthritis, Psoriatic; Tendon Injuries; Asthma; Lichen Planus; Arthritis, Juvenile; Uveitis; Arthritis; Inflammation; Plaque psoriasis; Behcet Syndrome; Crohn Disease; Gastroenteritis; Dermatitis, Atopic; Ichthyosiform Erythroderma, Congenital; Spondylitis, Ankylosing; Non-radiographic axial spondyloarthritis; Necrobiosis Lipoidica; Diabetes Mellitus, Type 1; Giant Cell Arteritis; Alopecia Areata; Pyoderma Gangrenosum; Lupus Erythematosus, Discoid; Metabolic Dysfunction-Associated Steatotic Liver Disease; Inflammatory Bowel Diseases; Multiple Sclerosis, Relapsing-Remitting; Rotator Cuff Injuries; Spondylarthritis; Arthritis, Rheumatoid; Spondylarthropathies; Netherton Syndrome; Ichthyosis; Lupus Nephritis; Graves Ophthalmopathy; Multiple Sclerosis | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SSGJ-608 | 608; SSGJ-608 | Phase 3 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing; Spondylarthritis; Psoriasis; Plaque psoriasis | Details |
| QX002N | QX-002N | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Spondylitis, Ankylosing; Asthma | Details |
| Roconkibart | JS005 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Non-radiographic axial spondyloarthritis; Spondylarthritis; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| Gumokimab | AK-111 | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd | Non-radiographic axial spondyloarthritis; Spondylarthritis; Spondylitis, Ankylosing; Skin Diseases; Psoriasis; Plaque psoriasis | Details |
| Izokibep | IMG-020; IMG020; ABY-035; AFB-035 | Phase 3 Clinical | Affibody Ab | Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa; Uveitis; Plaque psoriasis | Details |
| Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) | LZM－012; LZM012; XKH004; XKH-004 | Phase 3 Clinical | Beijing Kanova Biomedical Technology Co Ltd, Livzon Pharmaceutical Group Inc | Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| Secukinumab biosimilar (Bio-Thera Solutions) | BAT-2306 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Plaque psoriasis | Details |
| DMT-310 | DMT-310 | Phase 3 Clinical | Dermata | Acne Vulgaris; Rosacea | Details |
| CJM-112 | CJM-112 | Phase 2 Clinical | Novartis Pharma Ag | Acne Vulgaris; Triple Negative Breast Neoplasms; Multiple Sclerosis; Multiple Myeloma; Psoriasis; Asthma; Colorectal Neoplasms; Hidradenitis Suppurativa; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Sonelokimab | M-1095; ALX-0761; MSB-0010841 | Phase 2 Clinical | Ablynx Nv | Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa | Details |
| SIM-0335 | SIM-0335; SIM-335 | Phase 2 Clinical | BCY Pharm Co Ltd | Plaque psoriasis | Details |
| SCT-650C | SCT650C; SCT-650-C; SCT-650C | Phase 2 Clinical | SinoCelltech Ltd | Non-radiographic axial spondyloarthritis; Autoimmune Diseases; Plaque psoriasis | Details |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Depression; Anxiety; Hashimoto Disease; Frailty; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Healthy Aging; Inflammation; Sarcopenia | Details |
| CNTO-6785 | CNTO-6785; FTC-001 | Phase 1 Clinical | Morphosys Ag, Johnson & Johnson Innovative Medicine | Arthritis, Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Pulmonary Disease, Chronic Obstructive | Details |
| JNJ-61178104 | JNJ-61178104 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Autoimmune Diseases | Details |
| Secukinumab biosimilar (BioRay Pharmaceutical) | BR-201 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Autoimmune Diseases; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| JNJ-63823539 | JNJ-63823539 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Arthritis, Rheumatoid | Details |
| Secukinumab Biosimilar(Celltrion) | CT-P55 | Phase 1 Clinical | Celltrion Inc | Plaque psoriasis | Details |
| Secukinumab biosimilar (CSPC Pharmaceutical Group) | SYS6012; SYS-6012 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Plaque psoriasis | Details |
| Secukinumab biosimilar (Gan & Lee) | GLR1023; GLR-1023 | Phase 1 Clinical | Gan & Lee Pharmaceuticals | Plaque psoriasis | Details |
| anti-IL-17A humanized monoclonal antibody(Fontacea ) | Phase 1 Clinical | Shandong Fangtansi Biopharmaceutical Co Ltd | Plaque psoriasis | Details | |
| CMAB-015 | CMAB015; CMAB-015 | Phase 1 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Spondylitis, Ankylosing; Plaque psoriasis | Details |
| DC-853 | DC-853 | Phase 1 Clinical | Dice Therapeutics Inc | Immune System Diseases | Details |
| LEO-153339 | LEO-153339 | Phase 1 Clinical | Leo Pharma Inc | Details | |
| HY-1770 | HY1770; HT-17; HT17; HY-1770 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Dermatitis, Atopic; Plaque psoriasis | Details |
| ZL-1102 | ZL-1102; CB-001 | Phase 1 Clinical | Crescendo Biologics Ltd, Zai Lab (Shanghai) Co Ltd | Psoriasis | Details |
| UCB-0159 | UCB-0159 | Phase 1 Clinical | Ucb Sa | Autoimmune Diseases | Details |
| SSGJ-608 | 608; SSGJ-608 | Phase 3 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing; Spondylarthritis; Psoriasis; Plaque psoriasis | Details |
| QX002N | QX-002N | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Spondylitis, Ankylosing; Asthma | Details |
| Roconkibart | JS005 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Non-radiographic axial spondyloarthritis; Spondylarthritis; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| Gumokimab | AK-111 | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd | Non-radiographic axial spondyloarthritis; Spondylarthritis; Spondylitis, Ankylosing; Skin Diseases; Psoriasis; Plaque psoriasis | Details |
| Izokibep | IMG-020; IMG020; ABY-035; AFB-035 | Phase 3 Clinical | Affibody Ab | Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa; Uveitis; Plaque psoriasis | Details |
| Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) | LZM－012; LZM012; XKH004; XKH-004 | Phase 3 Clinical | Beijing Kanova Biomedical Technology Co Ltd, Livzon Pharmaceutical Group Inc | Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| Secukinumab biosimilar (Bio-Thera Solutions) | BAT-2306 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Plaque psoriasis | Details |
| DMT-310 | DMT-310 | Phase 3 Clinical | Dermata | Acne Vulgaris; Rosacea | Details |
| CJM-112 | CJM-112 | Phase 2 Clinical | Novartis Pharma Ag | Acne Vulgaris; Triple Negative Breast Neoplasms; Multiple Sclerosis; Multiple Myeloma; Psoriasis; Asthma; Colorectal Neoplasms; Hidradenitis Suppurativa; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Sonelokimab | M-1095; ALX-0761; MSB-0010841 | Phase 2 Clinical | Ablynx Nv | Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa | Details |
| SIM-0335 | SIM-0335; SIM-335 | Phase 2 Clinical | BCY Pharm Co Ltd | Plaque psoriasis | Details |
| SCT-650C | SCT650C; SCT-650-C; SCT-650C | Phase 2 Clinical | SinoCelltech Ltd | Non-radiographic axial spondyloarthritis; Autoimmune Diseases; Plaque psoriasis | Details |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Depression; Anxiety; Hashimoto Disease; Frailty; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Healthy Aging; Inflammation; Sarcopenia | Details |
| CNTO-6785 | CNTO-6785; FTC-001 | Phase 1 Clinical | Morphosys Ag, Johnson & Johnson Innovative Medicine | Arthritis, Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Pulmonary Disease, Chronic Obstructive | Details |
| JNJ-61178104 | JNJ-61178104 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Autoimmune Diseases | Details |
| Secukinumab biosimilar (BioRay Pharmaceutical) | BR-201 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Autoimmune Diseases; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
| JNJ-63823539 | JNJ-63823539 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Arthritis, Rheumatoid | Details |
| Secukinumab Biosimilar(Celltrion) | CT-P55 | Phase 1 Clinical | Celltrion Inc | Plaque psoriasis | Details |
| Secukinumab biosimilar (CSPC Pharmaceutical Group) | SYS6012; SYS-6012 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Plaque psoriasis | Details |
| Secukinumab biosimilar (Gan & Lee) | GLR1023; GLR-1023 | Phase 1 Clinical | Gan & Lee Pharmaceuticals | Plaque psoriasis | Details |
| anti-IL-17A humanized monoclonal antibody(Fontacea ) | Phase 1 Clinical | Shandong Fangtansi Biopharmaceutical Co Ltd | Plaque psoriasis | Details | |
| CMAB-015 | CMAB015; CMAB-015 | Phase 1 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Spondylitis, Ankylosing; Plaque psoriasis | Details |
| DC-853 | DC-853 | Phase 1 Clinical | Dice Therapeutics Inc | Immune System Diseases | Details |
| LEO-153339 | LEO-153339 | Phase 1 Clinical | Leo Pharma Inc | Details | |
| HY-1770 | HY1770; HT-17; HT17; HY-1770 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Dermatitis, Atopic; Plaque psoriasis | Details |
| ZL-1102 | ZL-1102; CB-001 | Phase 1 Clinical | Crescendo Biologics Ltd, Zai Lab (Shanghai) Co Ltd | Psoriasis | Details |
| UCB-0159 | UCB-0159 | Phase 1 Clinical | Ucb Sa | Autoimmune Diseases | Details |
This web search service is supported by Google Inc.
A-Z
